Latest familial hypercholesterolemia Stories
Submission of Application in Japan Marks an Important Milestone in Strategic Partnership With Amgen Astellas BioPharma THOUSAND OAKS, Calif., March 20, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN)
Analysis From Prespecified Exploratory Endpoints Presented in Late-Breaking Session at ACC.15 Showed Repatha Plus Standard of Care Lowered Cardiovascular Events THOUSAND OAKS, Calif., March
Data From PCSK9 Inhibitor Study Support Regulatory Filing in Japan THOUSAND OAKS, Calif., March 14, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new detailed data from the Phase
Data Evaluating the Effect of Repatha(TM)(Evolocumab) on LDL-C and Cardiovascular Events to be Featured in Late-Breaking Session THOUSAND OAKS, Calif., March 2, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN)
Congressional briefing highlights results of national patient research indicating the need to improve medication adherence, access to medication and enrollment of women in clinical trials, policy recommendations
PCSK9 inhibitors could cost the health care system as much as $150 billion annually WOONSOCKET, R.I., Feb.
FIND FH Initiative Unites Industry, Advocacy Community and Academia in an Effort to Support People Affected by Familial Hypercholesterolemia (FH), a Serious Genetic Disorder THOUSAND OAKS,
Additional Data Analysis Showed Every Two Week and Monthly Dosing Regimens of Evolocumab Were Clinically Equivalent THOUSAND OAKS, Calif., Nov.
Thirteen Presentations Include New Analyses of PCSK9 Inhibitor at Upcoming American Heart Association Scientific Sessions THOUSAND OAKS, Calif., Nov.
THOUSAND OAKS, Calif., Nov. 10, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S.
- A person in a secondary role, specifically the second most important character (after the protagonist).